Home > Maligne hematologie > Lymfoïde ziekten > Plasmaceldyscrasieën > Multipel myeloom > MajesTEC-9 / 64007957MMY3006

MajesTEC-9 / 64007957MMY3006

A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide

Deze print is 24 uur geldig na het aanmaken. Aangemaakt op: 22-12-2024, 20:04